Premium
JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus
Author(s) -
Klaeschen Anna Sophie,
Wolf Dominik,
Brossart Peter,
Bieber Thomas,
Wenzel Joerg
Publication year - 2017
Publication title -
experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.108
H-Index - 96
eISSN - 1600-0625
pISSN - 0906-6705
DOI - 10.1111/exd.13253
Subject(s) - ruxolitinib , in vivo , janus kinase , medicine , tofacitinib , lupus erythematosus , psoriasis , immunology , cxcl10 , systemic lupus erythematosus , janus kinase 1 , cancer research , chemokine , myelofibrosis , cytokine , biology , inflammation , bone marrow , antibody , disease , rheumatoid arthritis , microbiology and biotechnology
This study was stimulated by the clinical observation of a rapid response of a chilblain lupus patient to treatment with JAK 1/2‐kinase inhibitor ruxolitinib. We investigated the in vivo expression of phospho‐ JAK 2 in CLE skin samples as well as the immunomodulatory in vitro effect of ruxolitinib in cultured immortalized keratinocytes and in a 3D human epidermis model (epi CS ). Our results demonstrate that ruxolitinib significantly decreases the production of CLE ‐typical cytokines ( CXCL 10, CXCL 9, MxA) and might be a promising drug for future clinical studies in patients with CLE and related autoimmune skin diseases.